PDL BIOPHARMA INC - NOTE 2.750%12/0

CUSIP: 69329YAG9

Q3 2019 13F Holders as of 30 Sep 2019

Type / Class
Debt / NOTE 2.750%12/0
Market price (% of par)
96.16%
Total 13F principal
$48,086,008
Principal change
-$85,359,000
Total reported market value
$59,673,741
Number of holders
14
Value change
-$88,793,113
Number of buys
3
Number of sells
13

Quarterly Holders Quick Answers

What is CUSIP 69329YAG9?
CUSIP 69329YAG9 identifies 69329YAG9 - PDL BIOPHARMA INC - NOTE 2.750%12/0 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of PDL BIOPHARMA INC - NOTE 2.750%12/0 as of Q3 2019

As of 30 Sep 2019, PDL BIOPHARMA INC - NOTE 2.750%12/0 was held by 14 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $48,086,008 in principal (par value) of the bond. The largest 10 bondholders included Linden Advisors LP, SMH CAPITAL ADVISORS INC, SOROS FUND MANAGEMENT LLC, WOLVERINE ASSET MANAGEMENT LLC, MORGAN STANLEY, Pinnacle Holdings, LLC, Thrivent Financial for Lutherans, WELLS FARGO & COMPANY/MN, Context Capital Management, LLC, and SG Americas Securities, LLC. This page lists 14 institutional bondholders reporting positions for the Q3 2019 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.